- recruitingTherapeutic exploratory (Phase II)
A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia
This study is looking at a new medicine called ARO-APOC3 for people with a common type of high cholesterol and fats in their blood. Researchers want to see if it's safe to use long-term and how well it helps to lower these unhealthy levels.
Poland · Hungary · Netherlands - active not recruiting
Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia
This study looks at how a medicine called bempedoic acid (alone or with ezetimibe) works in real life for people with high cholesterol. It checks its effects on cholesterol levels, heart health, and any side effects over time.
Austria · Belgium · Germany - recruiting
A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
This study looks at how well a combination of three medicines – bempedoic acid, ezetimibe, and either rosuvastatin or atorvastatin – works together to lower 'bad' cholesterol (LDL-C) in people with high cholesterol. It also checks for any side effects in real-life medical care.
Austria · Belgium · Germany - active not recruiting
Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
This study looks at how well a medicine called inclisiran works for people with high cholesterol and helps prevent heart problems. We want to see if it lowers bad cholesterol and if people stick to taking it as part of their usual care.
Austria · China · Israel - recruitingPHASE3
Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days
This study compares two cholesterol-lowering medicines, obicetrapib and bempedoic acid, in adults with high cholesterol or mixed dyslipidemia. It looks at how well they reduce 'bad' cholesterol (LDL-C) and if they are safe, especially for people at higher risk of heart problems.
United Kingdom